Fengting Yan, MD, PhD, discusses unmet needs in breast cancer care and issues for specific subgroups of patients.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Manojkumar Bupathi, MD, MS, discussed his takeaways on physician decision-making for frontline metastatic renal cell carcinoma (RCC) treatment from a Case-Based Roundtable event.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

An expert discusses the safety profiles of combination regimens, effective strategies for managing side effects, and how to weigh the potential for toxicity versus efficacy/benefits when discussing ...

An expert discusses a treatment approach for the patient case above, how factors like brain metastases influence first-line treatment choices, reviews high-risk/CNS outcomes data from MARIPOSA and ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

A phase 2 trial shows promising results for pembrolizumab combined with cisplatin and radiation in treating unresectable ...

Suresh S. Ramalingam, MD, FACP, FASCO, emphasizes the role of community oncologists in translating new advancements in lung cancer research into widespread patient benefit.

A panelist discusses how four FDA-approved agents treat steroid-refractory cGVHD, including ibrutinib (65% response rate), ...

An expert shares clinical pearls with the community, offering insights and tips for managing patients effectively. EP: 1.A 55-Year-Old Man with EGFR-mutated Advanced/Metastatic NSCLC EP: 2.Recent ...

The DLL3-directed autologous chimeric antigen receptor (CAR) T-cell therapy LB2102 was well tolerated with no dose-limiting toxicities (DLTs) observed through dose level 4 (DL4), and it showed ...